Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01166646 · ClinicalTrials.gov registry record · Phase 2
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis
A Phase 2 study, sponsored by Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT01166646: Completed Phase 2 study, sponsored by Therapeutics.
NCT01166646 is a Phase 2 study that has completed, run by Therapeutics. The registered enrollment target is 43 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01166646, a Phase 2 study, has completed, sponsored by Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the investigational lotion is an effective treatment of moderate to severe plaque psoriasis in comparison to an approved cream.
Primary Outcome
Hypothalamic Pituitary-Adrenal (HPA)-Axis responses to Cosyntropin Stimulation Testing (CST) were dichotomized to normal and abnormal. An abnormal HPA Axis response (HPA Suppression) was defined as a 30-minute post-stimulation serum cortisol level of ≤18 μg/dL at the end of treatment.
Interventions
- DRUG Halobetasol Proprionate Lotion 0.05%
- DRUG Halobetasol Proprionate Cream 0.05%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
What the finished NCT01166646 record still lists
NCT01166646 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which Halobetasol Proprionate Lotion 0.05% is the first listed.
NCT01166646 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01166646 about?
NCT01166646 is a clinical study titled "Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis". The purpose of this study is to determine whether the investigational lotion is an effective treatment of moderate to severe plaque psoriasis in comparison to an approved cream.
What is the current status of trial NCT01166646?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2010-07. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01166646?
The interventions under investigation include: Halobetasol Proprionate Lotion 0.05% (DRUG), Halobetasol Proprionate Cream 0.05% (DRUG).
Who is sponsoring clinical trial NCT01166646?
This trial is sponsored by Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01166646's enrollment target sits among peer trials
43 1332nd of 2000 higher than 662 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia